文献速递关节外科

髋与膝关节多微生物假体周围感染:特征与管理

Polymicrobial periprosthetic joint infections of the hip and knee : characteristics and management.
PubMed 文献 · Bone Joint J · 2025-12-01

该回顾性队列研究纳入2013年1月至2020年5月在一家三级医疗中心接受两阶段或多阶段假体置换的39例多微生物假体周围感染患者(髋24例、膝15例),采用改良EBJIS标准诊断。结果显示髋与膝感染1、2、3年无感染生存率无显著差异,但4年后髋显著优于膝;复发感染10例(26%),难以治疗病原体显著影响治疗失败。

要点

  • 多微生物假体周围感染常见病原体为葡萄球菌(67%)、革兰阴性杆菌(38%)和肠球菌(36%)。
  • 髋与膝感染1、2、3年无感染生存率无显著差异,4年后髋显著优于膝。
  • 复发感染10例(26%),难以治疗病原体显著影响治疗失败。

核心结论

  • 多微生物假体周围感染仍是治疗困难的疾病,发病率高,需要量身定制的多学科方法。
  • 标准化的手术和抗生素策略可改善感染控制,但难以治疗病原体和既往翻修手术增加复发感染风险。
  • 长期功能结果不佳,突出需要进一步优化治疗方案以改善患者活动能力和生活质量。

研究设计与样本

  • 回顾性队列研究,在一家三级医疗中心开展,纳入2013年1月至2020年5月接受两阶段或多阶段假体置换的39例年龄≥18岁多微生物假体周围感染患者(髋24例、膝15例)。
  • 采用改良欧洲骨与关节感染学会(EBJIS)标准诊断假体周围感染,手术和抗生素治疗遵循标准化机构算法。
  • 结局采用Delphi国际多学科共识标准评估,功能按活动能力分类,统计分析包括Kaplan-Meier生存曲线和逻辑回归识别危险因素。

主要发现

  • 最常见分离病原体为葡萄球菌(n=26;67%)、革兰阴性杆菌(n=15;38%)和肠球菌(n=14;36%)。
  • 取出至再植入的中位间隔为91天,感染控制所需中位翻修次数为3次。
  • 术后抗生素方案常包括β-内酰胺类联合糖肽类或脂肽类,随后口服生物膜活性抗生素。
  • 髋与膝假体周围感染1、2、3年无感染生存率分别为76%(95%CI 52至89)和65%(95%CI 31至85),差异无统计学显著(p=0.121);4年后髋显著优于膝(76%(95%CI 52至89)vs 43%(95%CI 9至75);p<0.001)。
  • 复发感染10例(26%),难以治疗病原体显著影响治疗失败;13例(33%)恢复独立活动。

关键数值与推荐

  • 采用改良EBJIS标准诊断假体周围感染。
  • 结局评估采用Delphi国际多学科共识标准。
  • 感染控制所需中位翻修次数为3次,取出至再植入中位间隔91天。

临床怎么用

  • 手术和抗生素治疗遵循标准化机构算法,术后抗生素常包括β-内酰胺类联合糖肽类或脂肽类,随后口服生物膜活性抗生素。
  • 作者认为多微生物假体周围感染需要量身定制的多学科方法。
  • 作者指出需要进一步优化治疗方案以改善患者活动能力和生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to evaluate the clinical and microbiological characteristics, surgical and antibiotic strategies, and long-term outcomes in patients with polymicrobial periprosthetic joint infection (PJI). METHODS: This retrospective cohort study was undertaken at a tertiary healthcare centre and included patients aged ≥ 18 years with polymicrobial PJI treated with two-stage or multistage exchange of implants between January 2013 and May 2020. The modified European Bone and Joint Infection Society (EBJIS) criteria were used for the diagnosis of PJI. Surgical and antibiotic treatment followed a standardized institutional algorithm. Outcomes were assessed using Delphi international multidisciplinary consensus criteria and function was classified into categories of mobility. Statistical analyses included Kaplan-Meier survival curves and logistic regression for the identification of risk factors. RESULTS: A total of 39 patients were included; 24 hip and 15 knee PJIs. Staphylococci (n = 26; 67%), Gram-negative bacilli (n = 15; 38%), and enterococci (n = 14; 36%) were the most frequently isolated pathogens. The median interval between explantation and reimplantation was 91 days, with a median of three revisions required for infection control. Postoperative antibiotic regimens commonly included β-lactams with glycopeptides or lipopeptides, followed by biofilm-active oral antibiotics. The rates of infection-free survival at one, two, and three years were comparable for hip and knee PJIs (76% (95% CI 52 to 89) and 65% (95% CI 31 to 85), respectively; p = 0.121), but there was signicantly better long-term survival after four years for hip PJIs (76% (95% CI 52 to 89) vs 43% (95% CI 9 to 75); p < 0.001). Recurrent infection occurred in ten patients (26%), with difficult-to-treat (DTT) pathogens significantly influencing the failure of treatment. Functional outcomes varied, with 13 patients (33%) regaining independent mobilization. CONCLUSION: Polymicrobial PJI remains a difficult condition to treat, with high morbidity requiring a tailored multidisciplinary approach. While standardized surgical and antibiotic strategies improve infection control, DTT organisms, and previous revision procedures increase the risk of recurrent infection. The poor long-term functional outcomes highlight the need for further optimization of treatment protocols to enhance patients' mobility and quality of life.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Margaryan D, Dos Santos MV, Perka C, et al. Polymicrobial periprosthetic joint infections of the hip and knee : characteristics and management. Bone Joint J. 2025. PMID: 41319694. doi:10.1302/0301-620X.107B12.BJJ-2024-1656.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。